Finance

Lists
Outlook: 78.3% bullish·0.0% bearish
Go to analysis
BBIO:NASDAQ
BridgeBio Pharma Inc
$65.75
+0.61%
(+0.40) 1D
$66.50
+1.14% (+0.75)
Pre-market
Closed: Oct 12, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBIO...
Open
$65.35
High
$66.42
Low
$65.20
Mkt. cap
12.85B
Avg. vol.
2.72M
Volume
167.00
52-wk high
$93.42
52-wk low
$52.75
EPS
-$3.57
Beta
0.97
Shares outstanding
195.49M
No. of employees
1K
Open
$65.35
High
$66.42
Low
$65.20
Mkt. cap
12.85B
Avg. vol.
2.72M
Volume
167.00
52-wk high
$93.42
52-wk low
$52.75
EPS
-$3.57
Beta
0.97
Shares outstanding
195.49M
No. of employees
1K
News stories
From web sources and news partners
About BridgeBio Pharma Inc
CEONeil Kumar
Employees1K
Founded2015
HeadquartersPalo Alto, California, United States
SectorBiotechnology
Websitebridgebio.com
Analyst ratings
Based on 17 analysts giving stock ratings to BBIO in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for BBIO in the last 3 months.
Highest
Current $65.75
$156.00 (+137.26%)
Average
$111.38 (+69.40%)
Lowest
$94.00 (+42.97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luca Issi
RBC Capital
Buy
Maintained
$100.00
+52.1%
10/08/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$106.00
+61.2%
10/06/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$104.00
+58.2%
10/06/2026
Eliana Merle
Barclays
Buy
Maintained
$156.00
+137.3%
10/07/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
10/06/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$120.00
+82.5%
10/06/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
$110.00
+67.3%
09/24/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$130.00
+97.7%
09/14/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$110.00
+67.3%
08/31/2026
Andrew Tsai
Jefferies
Buy
Maintained
$110.00
+67.3%
08/31/2026
Biren Amin
Piper Sandler
Buy
Maintained
$115.00
+74.9%
08/31/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$110.00
+67.3%
08/29/2026
Eric Joseph
Citi
Hold
Maintained
$94.00
+43%
08/12/2026
Anupam Rama
J.P. Morgan
Buy
Reiterated
$111.00
+68.8%
08/12/2026
Danielle Brill
Truist Financial
Buy
Maintained
$107.00
+62.7%
08/12/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$97.00
+47.5%
08/11/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$102.00
+55.1%
08/11/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
$102.00
+55.1%
08/11/2026
Tiago Fauth
Raymond James
Buy
Maintained
$98.00
+49%
06/17/2026
Martin Auster
Raymond James
Hold
Downgraded
-
-
05/26/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
05/19/2026
William Pickering
Bernstein
Buy
Reiterated
$114.00
+73.4%
05/08/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$116.00
+76.4%
05/08/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
05/02/2026
Lisa Walter
RBC Capital
Buy
Initiated
$100.00
+52.1%
04/08/2026
Trevor Allred
Oppenheimer
Buy
Maintained
$81.00
+23.2%
02/25/2026
Last report
Aug 10, 2026
Fiscal period
Q2 2026
-$0.78 / -$0.58
-33.87%miss
Revenue / Est. (USD)
243.68M / 219.71M
+10.91%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
120.70M
154.18M
194.52M
243.68M
Cost of goods sold
6.56M
8.11M
9.94M
15.05M
Cost of revenue
6.56M
8.11M
9.94M
15.05M
Research and development expenses
112.87M
116.42M
126.64M
149.45M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
137.62M
158.08M
163.90M
186.26M
Operating expense
250.50M
274.50M
290.53M
335.71M
Total operating expenses
257.06M
282.61M
300.47M
350.76M
Operating income
-136.36M
-128.43M
-105.96M
-107.08M
Other non operating income
16.46M
11.82M
4.25M
5.59M
EBT including unusual items
-186.48M
-194.76M
-166.56M
-155.89M
EBT excluding unusual items
-177.64M
-183.62M
-166.56M
-155.89M
Income tax expense
-1.54M
-120.00K
-
-
Effective tax rate
0.83%
0.06%
-
-
Other operating expenses
-
-
-
-
Net income
-182.74M
-192.86M
-164.04M
-152.22M
Net profit margin
-151.40%
-125.09%
-84.33%
-62.47%
Earnings per share
-0.72
-0.94
-0.84
-0.78
Interest and investment income
6.24M
4.33M
6.25M
6.66M
Interest expense
-48.15M
-50.31M
-52.82M
-54.62M
Net interest expenses
-41.91M
-45.98M
-46.57M
-47.96M
Depreciation and amortization charges
-
-
-
-
EBITDA
-134.96M
-127.00M
-104.77M
-106.03M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps